Study
Breast Cancer Somatic Genetics Study
Study ID | Alternative Stable ID | Type |
---|---|---|
EGAS00001000195 | Cancer Genomics |
Study Description
We propose to definitively characterise the somatic genetics of ER+ve, HER2-ve breast cancer through generation of comprehensive catalogues of somatic mutations in 500 cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.
Study Datasets 13 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001000138 |
The expression data for this study can be found here: http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1088/and its SNP6 data can be found here:http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1087/
|
Illumina Genome Analyzer II,Illumina HiSeq 2000 | 58 |
EGAD00001000898 |
Cancers are ecosystems of genetically related clones, competing across space and time for limited resources. To understand the clonal structure of primary breast cancer, we applied genome and targeted sequencing to 295 samples from 49 patients’ tumors. The extent of subclonal diversification varied considerably among patients and encompassed many spatial patterns, including local growth, intraductal dissemination and clonal intermixture. Landmarks of disease progression, such as acquiring ... (Show More)
|
Illumina HiSeq 2000 | 42 |
EGAD00001001322 |
A comprehensive characterisation and analysis of human breast cancers through whole-genome sequencing.
|
Illumina HiSeq 2000 | 196 |
EGAD00001001323 |
A comprehensive characterisation and analysis of human breast cancers through genome-wide approaches through transcriptomics.
|
Illumina HiSeq 2000 | 59 |
EGAD00001001337 |
We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.
|
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina MiSeq | 607 |
EGAD00001001338 |
We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.
|
Illumina Genome Analyzer II,Illumina HiSeq 2000 | 49 |
EGAD00001001350 |
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
|
Illumina HiSeq 2000 | 8 |
EGAD00001002237 |
The disordered transcriptomes of cancer encompass direct effects of somatic mutation on transcription; co-ordinated secondary alterations in transcriptional pathways; and increased transcriptional noise. To catalogue the rules governing how somatic mutation Overall, 59% of 6980 exonic substitutions were expressed. Compared to other classes, nonsense mutations showed lower expression levels than expected with patterns characteristic of nonsense-mediated decay. 14% of 4234 genomic ... (Show More)
|
Illumina Genome Analyzer II,Illumina HiSeq 2000 | 59 |
EGAD00001002696 |
Recurrent breast cancer is almost universally fatal. We characterize 170 patients locally relapsed or distant metastatic cancers using massively parallel sequencing. We identify that the relapse-seeding clone disseminates late from the primary tumor. TP53 and AKT1 appear to be enriched in ER-positive cancers predisposed to relapse. Mutation acquisition continues at relapse as the same mutation signatures continue to operate and new signatures, such as that caused by radiotherapy appear de novo. ... (Show More)
|
HiSeq X Ten,Illumina HiSeq 2000 | 58 |
EGAD00001002740 |
We propose to definitively characterise the somatic genetics of breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing.
|
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina MiSeq | 164 |
EGAD00010000915 |
Affymetrix SNP6.0 breast cancer genome sequencing data
|
Affymetrix SNP6.0 | 344 |
EGAD00010000917 |
399 tumors profiled using Agilent miRNA microarrays (Product Number G4872A, design ID 046064). The arrays are based on miRBase release 19.0 and 2006 human miRNAs are represented. 150 ng total RNA was used as input.
|
Agilent miRNA microarrays | 399 |
EGAD00010001079 |
Affymetrix SNP6.0 array breast cancer data
|
Affymetrix SNP6.0 | 66 |
Who archives the data?

Publications
Citations
Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...

Retrieving...
